ANDROBIOSYS, INC.

Basic Information

875 Ellicott St
BUFFALO, NY, 14203-1070

http://www.androbiosys.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 193493157
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 5


  1. Circulating Prostate Cancer Progenitor Cell Assay Development

    Amount: $747,553.00

    The technical objectives of this Phase II project are to identify unique biomarkers and produce molecular, antibody and peptide reagents that are specific for human prostate cancer progenitor stem cel ...

    STTR Phase II 2011 ArmyDepartment of DefenseDepartment of Defense
  2. Platelet-based Nanoparticle Therapy for Prostate Cancer

    Amount: $999,642.00

    The goal of this Phase II proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The ...

    SBIR Phase II 2010 Department of Health and Human Services
  3. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

    Amount: $128,052.00

    DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatm ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

    Amount: $139,945.00

    DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved p ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. PLATELET-BASED NANOPARTICLE THERAPY FOR PROSTATE CANCER

    Amount: $149,994.00

    The goal of this proposal is to develop directed energy transfer methods for imaging, tissue ablation and release of therapeutic modalities targeted to the vasculature of prostate cancer. The platform ...

    SBIR Phase I 2008 Department of Health and Human Services
  6. Circulating Prostate Cancer Progenitor Cell Assay Development

    Amount: $96,765.00

    This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate ...

    STTR Phase I 2008 ArmyDepartment of DefenseDepartment of Defense

Agency Micro-sites

US Flag An Official Website of the United States Government